AbCellera Biologics Inc. (FRA:8QQ)
Germany
· Delayed Price · Currency is EUR 3.098
+0.098 (3.27%)
At close: Dec 5, 2025
AbCellera Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 35.33 | 28.83 | 38.03 | 485.42 | 375.2 | 233.16 | Upgrade
|
| Revenue Growth (YoY) | 7.17% | -24.17% | -92.17% | 29.38% | 60.92% | 1907.88% | Upgrade
|
| Cost of Revenue | 182.81 | 167.26 | 175.66 | 174.32 | 107.58 | 56.54 | Upgrade
|
| Gross Profit | -147.49 | -138.43 | -137.63 | 311.11 | 267.63 | 176.62 | Upgrade
|
| Selling, General & Admin | 85.18 | 85.49 | 75.18 | 66.76 | 48.76 | 15.75 | Upgrade
|
| Operating Expenses | 81.79 | 144.34 | 99.57 | 86.2 | 63.21 | 20.59 | Upgrade
|
| Operating Income | -229.28 | -282.77 | -237.21 | 224.91 | 204.41 | 156.03 | Upgrade
|
| Interest Expense | - | - | - | - | - | -6.81 | Upgrade
|
| Interest & Investment Income | 31.08 | 38.47 | 42.25 | 16.08 | 3.33 | 0.29 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.47 | 11.2 | 13.1 | 8.21 | 11.91 | 8.32 | Upgrade
|
| EBT Excluding Unusual Items | -188.73 | -233.1 | -181.86 | 249.2 | 219.65 | 157.83 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.9 | 17.4 | 3.9 | -1.7 | -0.5 | - | Upgrade
|
| Asset Writedown | -32 | -32 | - | -8.4 | - | - | Upgrade
|
| Other Unusual Items | 14.9 | 47.3 | 3.93 | - | - | - | Upgrade
|
| Pretax Income | -204.93 | -200.4 | -174.03 | 239.1 | 219.15 | 157.83 | Upgrade
|
| Income Tax Expense | -33.25 | -37.54 | -27.63 | 80.58 | 65.69 | 38.92 | Upgrade
|
| Net Income | -171.68 | -162.86 | -146.4 | 158.52 | 153.46 | 118.92 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 33.82 | Upgrade
|
| Net Income to Common | -171.68 | -162.86 | -146.4 | 158.52 | 153.46 | 85.1 | Upgrade
|
| Net Income Growth | - | - | - | 3.29% | 29.05% | - | Upgrade
|
| Shares Outstanding (Basic) | 298 | 294 | 289 | 285 | 276 | 159 | Upgrade
|
| Shares Outstanding (Diluted) | 298 | 294 | 289 | 315 | 318 | 263 | Upgrade
|
| Shares Change (YoY) | 1.57% | 1.79% | -8.15% | -1.09% | 20.96% | 73.88% | Upgrade
|
| EPS (Basic) | -0.58 | -0.55 | -0.51 | 0.56 | 0.56 | 0.53 | Upgrade
|
| EPS (Diluted) | -0.58 | -0.55 | -0.51 | 0.50 | 0.48 | 0.45 | Upgrade
|
| EPS Growth | - | - | - | 4.17% | 6.21% | - | Upgrade
|
| Free Cash Flow | -153.11 | -186.95 | -120.82 | 206.7 | 186.13 | 13.02 | Upgrade
|
| Free Cash Flow Per Share | -0.51 | -0.64 | -0.42 | 0.66 | 0.58 | 0.05 | Upgrade
|
| Gross Margin | - | - | - | 64.09% | 71.33% | 75.75% | Upgrade
|
| Operating Margin | -649.05% | -980.70% | -623.82% | 46.33% | 54.48% | 66.92% | Upgrade
|
| Profit Margin | -485.99% | -564.83% | -385.00% | 32.66% | 40.90% | 36.50% | Upgrade
|
| Free Cash Flow Margin | -433.43% | -648.40% | -317.75% | 42.58% | 49.61% | 5.58% | Upgrade
|
| EBITDA | -232.66 | -223.92 | -212.81 | 244.35 | 218.88 | 160.87 | Upgrade
|
| EBITDA Margin | - | - | - | 50.34% | 58.34% | 69.00% | Upgrade
|
| D&A For EBITDA | -3.39 | 58.85 | 24.4 | 19.44 | 14.47 | 4.84 | Upgrade
|
| EBIT | -229.28 | -282.77 | -237.21 | 224.91 | 204.41 | 156.03 | Upgrade
|
| EBIT Margin | - | - | - | 46.33% | 54.48% | 66.92% | Upgrade
|
| Effective Tax Rate | - | - | - | 33.70% | 29.97% | 24.66% | Upgrade
|
| Revenue as Reported | 35.33 | 28.83 | 38.03 | 485.42 | 375.2 | 233.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.